Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Front Pharmacol. 2023 May 3:14:1207356. doi: 10.3389/fphar.2023.1207356. eCollection 2023.

Jochen G Mainz^{1

2}, Carlos Zagoya¹, Louise Polte¹, Lutz Naehrlich^{3

4}, Lenny Sasse³, Olaf Eickmeier⁵, Christina Smaczny⁵, Anton Barucha¹, Lilith Bechinger¹, Franziska Duckstein¹, Ludwik Kurzidim^{1

6}, Patience Eschenhagen⁶, Laura Caley⁷, Daniel Peckham^{7

8}, Carsten Schwarz⁶

¹ Cystic Fibrosis Center, Brandenburg Medical School (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany.
² Faculty of Health Sciences Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, The Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany.
³ Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.
⁴ Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Giessen, Germany.
⁵ Christiane Herzog CF-Zentrum Frankfurt am Main, Universitätsklinikum Frankfurt am Main CF-Zentrum, Frankfurt am Main, Germany.
⁶ CF-Zentrum Westbrandenburg, Campus Potsdam, Klinikum Westbrandenburg, Potsdam, Germany.
⁷ Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
⁸ Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.877118.].

Keywords: CFTR modulators; elexacaftor; gastrointestinal; patient reported outcome measure; symptom score.